(Q39375372)

11 September 2017

Chronic treatment of mitochondrial disease patients with dichloroacetate (English)

1 reference

11 September 2017

0 references

mitochondrial disease

1 reference

4

1 reference

11 September 2017

2

Robert K Naviaux

1 reference

11 September 2017

Bruce A Barshop

1

1 reference

11 September 2017

Karen A McGowan

3

1 reference

11 September 2017

William L Nyhan

5

1 reference

11 September 2017

Amalia Loupis-Geller

6

1 reference

11 September 2017

Richard H Haas

7

1 reference

11 September 2017

1 September 2004

1 reference

Molecular Genetics and Metabolism

11 September 2017

1 reference

11 September 2017

83

1 reference

11 September 2017

1-2

1 reference

11 September 2017

138-149

1 reference

Lipoamide dehydrogenase deficiency with primary lactic acidosis: favorable response to treatment with oral lipoic acid

11 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

An improved method for preparation of samples for the simultaneous assay of some antiepileptic drugs by gas-liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Coenzyme Q-responsive Leigh's encephalopathy in two sisters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Treatment of Kearns-Sayre syndrome with coenzyme Q10

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

The pharmacology of dichloroacetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Metabolic Effects of Dichloroacetate in Patients with Diabetes Mellitus and Hyperlipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Dichloroacetate effects on glucose and lactate oxidation by neurons and astroglia in vitro and on glucose utilization by brain in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Lactate induced excitotoxicity in hippocampal slice cultures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Treatment of lactic acidosis: effects of dichloroacetate on lactate and pyruvate levels in the cerebrospinal fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Treatment of chronic congenital lactic acidosis by oral administration of dichloroacetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

HL-A antigens in adult polymyositis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Lactic acidosis due to pyruvate carboxylase deficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Dichloroacetate in the treatment of congenital lactic acidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Therapeutic effect and [123I]IMP SPECT findings of sodium dichloroacetate in a patient with MELAS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Transient lactic acidosis and hyperalaninaemia associated with neonatal hyperinsulinaemic hypoglycaemia: the effects of dichloroacetate (DCA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Therapeutic effect of sodium dichloroacetate on visual and auditory hallucinations in a patient with MELAS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Beneficial effect of sodium dichloroacetate in muscle cytochrome C oxidase deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Control of oxygen free radical formation from mitochondrial complex I: roles for protein kinase A and pyruvate dehydrogenase kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Plasma concentrations and metabolic effects of intravenous sodium dichloroacetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Fructose load test—an in vivo screening test designed to assess pyruvate dehydrogenase activity and interconversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Metabolic effects of dietary fructose in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Dichloroacetate increases glucose use and decreases lactate in developing rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Magnetic resonance spectroscopy: use in monitoring MELAS treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Clinical and radiologic improvements in mitochondrial encephalomyelopathy following sodium dichloroacetate therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Therapy of complex I deficiency: peripheral neuropathy during dichloroacetate therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Reduction of serum cholesterol in two patients with homozygous familial hypercholesterolemia by dichloroacetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

Effect of sodium dichloroacetate on human pyruvate metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2004.06.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMGME.2004.06.009

1 reference

11 September 2017

1 reference